Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries

Int J Clin Pharm. 2023 Aug;45(4):989-998. doi: 10.1007/s11096-023-01603-y. Epub 2023 Jun 7.

Abstract

Background: In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR).

Aim: The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006-2020), and the reported AMR in Pseudomonas aeruginosa (2013-2020) in Serbia and to compare with data from eight European countries (2015-2020).

Method: Joinpoint regression was used to analyse antibiotic utilization data (2006-2020) and the reported AMR in Pseudomonas aeruginosa (2013-2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries.

Results: There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aeruginosa, Serbia (p < 0.05) (2018-2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseudomonas aeruginosa an increased trend was observed, Serbia (2013-2020). A decrease in both the utilization of aminoglycosides, Serbia (p < 0.05) (2006-2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015-2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015-2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015-2020).

Conclusion: The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.

Keywords: Antibiotic utilization; Antimicrobial resistance; Pseudomonas aeruginosa; Serbia.

MeSH terms

  • Aminoglycosides
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • Ceftazidime
  • Fluoroquinolones
  • Humans
  • Piperacillin, Tazobactam Drug Combination
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa
  • Serbia

Substances

  • Ceftazidime
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Aminoglycosides
  • Fluoroquinolones
  • Piperacillin, Tazobactam Drug Combination